© Reuters. FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble/File Photo
(Reuters) – AstraZeneca (NASDAQ:) said on Thursday that a combination of its cancer drug Lynparza and abiraterone has been approved in the United States for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.
The company said the combination treatment reduced the risk of disease progression or death by 76% compared with usage of abiraterone alone.
Read the full article here
